Dr. Robert Lanza, Chief Scientific Officer of Ocata Therapeutics Awarded the Honor of iPSC Industry Influencer

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Dr. Robert Lanza, Chief Scientific Officer of Ocata Therapeutics has been awarded the honor of iPSC industry influencer by BioInformant, a leading research firm serving the stem cell sector. Dr. Lanza was honored both for his specific involvement in early-stage, pioneering research in the area of induced Pluripotent Stem Cells, or “iPSCs”, as we